Abstract:Abstract The DNA damage response (DDR) protein DNA Polymerase θ (Polθ) is synthetic lethal with homologous recombination (HR) factors and is therefore a promising drug target in BRCA1/2 mutant cancers. We discover an allosteric Polθ inhibitor (Polθi) class with 4–6 nM IC 50 that selectively kills HR-deficient cells and acts synergistically with PARP inhibitors (PARPi) in multiple genetic backgrounds. X-ray crystallography and biochemistry reveal that Polθi selectively inhibits Polθ polymerase (Polθ-pol) in the closed conformation on B-form DNA/DNA via an induced fit mechanism. In contrast, Polθi fails to inhibit Polθ-pol catalytic activity on A-form DNA/RNA in which the enzyme binds in the open configuration. Remarkably, Polθi binding to the Polθ-pol:DNA/DNA closed complex traps the polymerase on DNA for more than forty minutes which elucidates the inhibitory mechanism of action. These data reveal a unique small-molecule DNA polymerase:DNA trapping mechanism that induces synthetic lethality in HR-deficient cells and potentiates the activity of PARPi.

What problem does this paper attempt to address?

The aim of this paper is to solve the following problems: 1. **Develop small - molecule inhibitors targeting Pol θ**: The paper describes the discovery of a new small - molecule inhibitor (Pol θi), which can specifically inhibit the activity of DNA polymerase θ (Pol θ). This inhibitor shows selective killing effects in HR - deficient cells and has a synergistic effect when combined with PARP inhibitors (PARPi). 2. **Overcome the resistance to PARP inhibitors**: PARP inhibitors (PARPi) have achieved remarkable results in the treatment of cancers with BRCA1/2 mutations, but some patients will develop resistance. The paper explores how to overcome this resistance by inhibiting Pol θ, especially in cells with various genetic backgrounds. 3. **Elucidate the mechanism of action of Pol θ inhibitors**: Through X - ray crystallography and biochemical experiments, the paper reveals in detail how Pol θ inhibitors specifically bind to the closed conformation of Pol θ through the induced fit mechanism, thereby trapping it on DNA for more than 40 minutes and resulting in the inhibition of its activity. ### Specific problem analysis #### 1. Discovery of new Pol θ inhibitors - **Objective**: Develop a highly efficient and selective Pol θ inhibitor. - **Methods**: Through high - throughput screening and medicinal chemistry optimization, compounds RTx - 161 and RTx - 152 were discovered, and their IC50 values for Pol θ are 4 - 6 nM respectively. - **Results**: These inhibitors show significant selective killing effects in HR - deficient cells and show low to no toxicity in BRCA2 - null HCT116 and DLD1 cells. #### 2. Overcome the resistance to PARP inhibitors - **Background**: PARP inhibitors are effective in cancers with BRCA1/2 mutations, but there is a problem of resistance. - **Methods**: The combined use effect of RTx - 161 and PARP inhibitors (such as Olaparib) was studied. - **Results**: The combined use of RTx - 161 and Olaparib shows a strong synergistic effect in BRCA2 - null HCT116 and DLD1 cells, significantly reducing the cell resistance to Olaparib. In addition, similar effects were also observed in other cell lines carrying BRCA2 mutations. #### 3. Elucidate the mechanism of action of Pol θ inhibitors - **Methods**: The structure of Pol θ bound to the inhibitor RTx - 152 was resolved by X - ray crystallography. - **Results**: - **Structural features**: RTx - 152 binds to an allosteric pocket in the closed conformation of Pol θ, which is composed of multiple α - helices in the fingers domain. - **Induced fit mechanism**: The binding of RTx - 152 causes the movement of surrounding residues, forming a stable complex, which traps Pol θ on DNA for more than 40 minutes. - **Selective inhibition**: RTx - 152 is only effective when Pol θ is in the closed conformation, and is ineffective in the open conformation (such as binding on A - form DNA/RNA). ### Conclusion This paper successfully developed highly efficient and selective Pol θ inhibitors (RTx - 161 and RTx - 152). These inhibitors not only show significant killing effects in HR - deficient cells, but also can overcome the resistance to PARP inhibitors. Through detailed structural and biochemical analysis, the paper reveals that these inhibitors specifically bind to the closed conformation of Pol θ through the induced fit mechanism, thereby trapping it on DNA and resulting in the inhibition of its activity. These findings provide important theoretical basis and technical support for the development of a new generation of precision anti - cancer drugs.

Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

Abstract 4532: Discovery of DAT-1000A, a potent Polθ inhibitor that significantly enhances anti-tumor efficacy in combination with PARP inhibitor in homologous-recombination-deficient tumors

Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors

Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM

Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH)

Abstract 512: Identification of SS008871, a novel Polθ inhibitor that effectively inhibits tumors with homologous recombination deficiency in vitro and in vivo

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib

Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells

Abstract LB273: Pharmacological synthetic lethality by co-inhibition of PARP and HDAC enzymes

Discovery of Potent Isoindolinone Inhibitors That Target an Active Conformation of PARP1 Using DNA‐Encoded Libraries

Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy

DNA Polymerase Θ: a Multifunctional and Error-prone DNA End Repair Enzyme

Structural basis for allosteric PARP-1 retention on DNA breaks

Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition

Abstract 7126: Synergistic combinations and tissue type-specificity of compounds targeting components of the DNA damage response pathway in 2D culture and 3D spheroid cell viability assays

Discovery of 3-hydroxymethyl-azetidine derivatives as potent polymerase theta inhibitors

Abstract 1058: Evaluation of a novel class of bifunctional DNA alkylating agent and PARP inhibitor

Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer

Identification of [1,2,4]Triazolo[4,3- a ]pyrazine PARP1 inhibitors with overcome acquired resistance activities

Abstract 7119: Clinic-ready Polθ inhibitor SYX1097 suppresses solid tumors in vivo